A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

NCT06511570 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: sabirnetug (ACU193)
COMBINATION_PRODUCT: Sabirnetug + rHuPH20

Sponsor

Acumen Pharmaceuticals